Background Smoking accounts for .50% of bladder cancers (BCs) in men and 30% in women. Our aim is to explore this large discrepancy by contrasting countries with distinct smoking patterns and habits as these might explain sex differences for BC.
Introduction
In 2004, bladder cancer (BC) was estimated to be the fourth most common cancer among men and the 14th among women in the European Union (cumulative risk of 2.82 and 0.52%, respectively). Apart from age, sex and a small number of occupational groups (dye workers, rubber workers, leather workers, painters, truck drivers and aluminium workers), smoking is the only risk factor of BC for which clear epidemiological evidence has been found. 1, 2 Cigarette smoking has been proposed to account for more than 50% of BCs in men and 30% in women. This association between active (cigarette) smoking and BC has been confirmed by more than 35 case -control studies and 10 cohort studies. 1,3 -5 The European Prospective Investigation into Cancer and Nutrition (EPIC), for instance, found an increased risk of BC for both current [incidence rate ratio 3.96; 95% confidence interval (CI): 3.07 -5.09] and ex-smokers (2.25; 95% CI: 1.74 -2.91). 3 Moreover, the tobacco smoke constituent 4-aminobiphenyl (4-ABP) is a well-established risk factor for BC. 6 -10 Smokers of blond tobacco are found to be at lower risk for BC than those of black tobacco, 6, 11 which is likely explained by the larger amount of 4-ABP in dark tobacco. 7, 12, 13 In addition, the concentration of 4-ABP in sidestream smoke is over 10 times greater than in mainstream smoke. 14 However, a recent meta-analysis did not find evidence for an association between SHS and BC risk (pooled RR: 0.99; 95% CI: 0.86; 1.14), comparing non-smokers with and without SHS exposure. Even though it is possible that there is no association, assessment of SHS is subject to measurement error and may explain this null finding. 15 Despite all this existing knowledge about BC risk and smoking (active or passive), it remains unclear why there is such a large discrepancy in BC incidence by sex. In 2004, the estimated BC incidence in the European Union was 91.0 for men and 25.1 for women per 100 000. 16 The current study aims to further explore this sex discrepancy by contrasting three Western European countries with distinct smoking patterns and habits as it is thought that distinguished smoking habits and cigarette characteristics (smoking prevalence, cigarette consumption and preference for tobacco) might explain these sex differences in BC rates. 16, 17 The three included countries (Spain, the UK and Sweden) were selected based on their current relation to the larger tobacco epidemic with respect to cigarette smoking and its effect on chronic diseases, and on the different types of cigarettes dominating each country's market. Currently, Spain is said to be in stage 3 of the tobacco epidemic, whereas the UK and Sweden are believed to be in stage 4.
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In addition, dark tobacco dominates the market in Spain, whereas blond tobacco is common in Sweden and the UK. This study also focuses on lung cancer (LC) as it is strongly associated with smoking (almost 90%). Thus, any temporal changes in LC rates across contrasting countries might indirectly reflect the recent and past population-specific tobacco control efforts. 19 LC rates have already shown sex-wise temporal variations that are mainly attributed to changing smoking habits by sex. A similar pattern for BC rates might also support a similar role for changing smoking habits by sex in BC. The converse might suggest factors other than active cigarette smoking contributing to changing temporal rates in BC rates by sex. Because of methodologic difficulty in modeling country-specific tobacco control data in a simple descriptive model, we set out to examine temporal patterns for BC across these three contrasting countries, using LC rates as surrogate for past and recent population-specific tobacco control.
Methods

Data collection
Average annual BC incidence statistics ( per 100 000) were obtained from the Cancer Incidence in Five Continents (CI5) VIII detailed database. 20 Incidence is thought to be a better indicator of the BC burden as it increased by more than 50% between 1950 and 1987, whereas mortality declined by 35% over the past 50 years. 1 Sweden had countrywide world age-adjusted incidence by sex from 1958 to 1997. For Spain and the UK, data are reported per region and were available from 1973 to 1997 and 1960 to 1997, respectively. To get countrywide estimates for these countries, the age-adjusted incidence was averaged over the number of regions reporting BC incidence per time period. This could potentially cause larger within-country variation as the quality of cancer registration might locally differ within countries.
To estimate average annual smoking habits, smoking prevalence and number of cigarettes smoked per day (cigarette consumption) were reported by year and sex. Consumption data for other tobacco products were not collected as it has been shown that the potency of carcinogenicity of cigars and pipes is much lower than for cigarettes, and the latter one are still the most popular form of tobacco use. 4 , 21 The International Smoking Statistics gave estimates for both smoking prevalence and cigarette consumption up until 1995. 22 Smoking prevalence after 1995 was obtained from the WHO Regional Office for Europe, Tobacco Control Database. 23 When several values for smoking prevalence or cigarette consumption were reported for 1 year, the average value was used for the annual estimate. Finally, estimates for missing values were calculated by using modelbased imputation, more specifically via simple linear regression.
Current prevalence of smoking, however, is a poor proxy for cumulative hazards of smoking, which depend on factors such as age at which smoking began, duration of smoking, the number of cigarettes smoked per day, cigarette characteristics such as tar and nicotine content or filter type and smoking behavior such as degree of inhalation. 24 Ninety percent of male LCs is associated with cigarette smoking, and temporal patterns in LC are strongly influenced by individual smoking characteristics. LC rates are thus important surrogate measures for explaining changes in population smoking exposure levels as there is limited information on the historical patterns of population smoking exposure levels and tobacco use as well as second-hand-smoke (SHS) exposure levels. 19 Therefore, annual age-standardized LC death rates ( per 100 000), as a proxy measure of individual cumulative smoke-load, were obtained from the World Health Organization's mortality database. 18, 25, 26 Countrywide world age-adjusted rates by sex were available for Sweden from 1951 to 2002, for Spain from 1951 to 2004 and for the UK from 1950 to 2004. The age-standardized rates were adjusted to the world population (1960) and LC diagnosis, similar to BC, was based on the International Classification of Disease, 10th revision (ICD-10)-resulting in rates that are comparable over time. 27 The use of death rates for LC versus incidence rates for BC did not cause major restrictions in the interpretation of the results as it has been estimated that only 15% of all patients with LC are still alive 5 years after diagnosis. 28 
Data analysis
The temporal patterns for annual BC incidence rates and tobacco data were examined by calculating annual percent changes (APCs) in disease rates. These APCs were estimated with log-linear Poisson regression models, using the US National Cancer Institute's Joinpoint Regression Analysis Program (version 3.0), as applied across several European countries to identify temporal patterns in cancer death rates. 29 -31 Age 35 has been proposed as the lowest age for considering the impacts of smoking. 24 BC incidence rises steeply with age in both sexes after age 50 and age groups were therefore collapsed into three broad age bands: 35-49, 50-64 and 65þ. 32 Joinpoint analysis was also used to study temporal patterns for LC death rates, smoking prevalence and cigarette consumption by sex. On a log scale to these variables, the joinpoint analysis fits a series of joined straight lines for which each joinpoint denotes a statistically significant change in trend. The bestfitting points are the years of the dependent variable, e.g. BC rates, that change significantly (increasing or decreasing trends).
Apart from joinpoint regression modeling, the remaining analyses were performed using SAS 9.1.3 (SAS Institute, Cary, NC, USA) and Microsoft Excel w (Microsoft, Redmond, WA, USA) software packages.
Results
A comparison of overall APCs for BC incidence rates, LC mortality rates and smoking prevalence for both sexes in each country is shown in Fig. 1 .
Spain
Spanish BC incidence and LC death rates as well as smoking prevalence and average daily cigarette consumption are shown in Figs 2 and 3 for men and women, respectively. Male cancer rates showed almost similar temporal patterns (an increase), but LC death rates were 1.7 (95% CI: 1.21; 2.23) times higher than BC incidence. However, female LC death rates started off at a much higher rate than BC (2.4 versus 1.0 per 100 000), and during follow-up, both cancer rates reached the same magnitude (in 1994: both LC and BC rates are 4.1 per 100 000).
The APCs and joinpoint analyses for Spain are displayed in Tables 1 and 2 for men and women, respectively. Overall, BC incidence APCs increased in a similar fashion for both sexes; 3.79% for men and 3.63% for women. Annual male LC death rates began to decrease in the last decade (APC ¼ 20.37%), whereas APCs in male cigarette consumption and smoking prevalence declined during the entire second half of the twentieth century. In contrast, female cigarette consumption, smoking prevalence and LC mortality rates showed increasing APCs during this time.
Sweden
Figures 2 and 3 show the annual BC incidence and LC death rates as well as smoking prevalence and average daily cigarette consumption for the Swedish population in 1958 -97 for men and women, respectively. Male cancer rates tended to follow a similar pattern (an increase followed by a plateau), but after 1980, the gap between both cancer rates reduced. Female cancer rates, on the other hand, have different patterns: LC rates were decreasing over time, whereas BC rates were increasing. Tables 1 and 2 illustrate the APCs and joinpoint analyses for Sweden for men and women, respectively. BC incidence rates showed an increasing overall APC, but during the last two decades (1970 -97), the APCs were small for all age categories across both sexes. However, the decline in APC for smoking prevalence is faster among men. Furthermore, since 1977, the APC for LC mortality rates was declining in men only. Tables 1 and 2 , respectively. For both men and women, the APC of overall BC decreased over time. Also male smoking prevalence and cigarette consumption had an overall significant decline in APC and as of 1965, the APC in LC mortality rates also started to decline in men. For women, APCs in LC mortality, cigarette consumption and smoking prevalence declined over time; however, the degree to which APC in smoking prevalence declined was slightly slower for women.
TOBACCO USE AND BC PATTERNS
1 APCs with 95% CI of BC incidence rates, LC death rates, cigarette consumption and smoking prevalence and joinpoint analysis among males in Spain (1973 -97), Sweden (1958 -97) and
Discussion
Three consistent findings emerged in the most recent temporal patterns for bladder and LC rates when analyzed across three contrasting Western European countries: (i) comparison of the most recent slopes of BC incidence to the earliest slopes (1960s) of LC mortality confirms the tobacco epidemic stage of each country and shows a similar gradient in both sexes for BC incidence in all three countries; (ii) comparison of these recent slopes of BC incidence across countries in both sexes to the earliest slopes of smoking prevalence (early 1960s) demonstrates a different pattern and suggests a cohort effect of a longer lag period between smoking and BC (40-50 years); and (iii) comparison of the most recent slopes of BC incidence illustrates that these are greater than the earliest slopes of LC mortality (2/3 times).
Cigarette smoking and specific occupational exposures are currently the main known causes of urinary BC.
1,2 More specifically, a positive dose-response relationship is established with both number of cigarettes smoked daily and number of years of smoking. Upon cessation of cigarette smoking, the excess risk of urinary BCs falls over 30% after 1 -4 years and over 60% after 25 years of cessation. As already mentioned, 4-ABP is the main bladder carcinogen and is highly available in dark tobacco. The other chemical carcinogens for BC come from exposures to aromatic amines in chemical industry places and in the rubber industry. Other agents found to be associated with urinary BC are polycyclic aromatic hydrocarbons, which are used in aluminum production, coal gasification, coal tars, roofing and carbon black manufacture. Interestingly, in contrast to patterns for tobacco smoking, the pattern of BC risk among women is similar to that in men when looking at occupational exposures. 1, 2 In addition to tobacco and occupational exposure, some increased risk among European Caucasians has been found from medications including agents such as phenacetin, chlornaphazine and cyclophosphamide. However, despite the extensive amount of research on BC etiology, it is still unclear why there are such strong sex differences in incidence rates.
Our study findings are consistent with the changing tobacco epidemic across the countries analyzed. When comparing the earliest slopes of LC mortality, which normally represents the smoking trends of the 1930s and 1940s, with the most recent slopes of BC incidence across the three countries for both sexes, we observed that Spain has the highest, the UK the lowest and Sweden the intermediate slopes. This pattern shows that Spain is in stage 3 and the UK and Sweden in stage 4. 18 Stage 3 refers to a plateau in smoking patterns among males, whereas stage 4 is already associated with a plateau and then decline in smoking in females. According to this 'stage definition', the trends in smoking prevalence are followed two to three decades later by similar peaks and falls in mortality caused by smoking. 18 The most recent APCs for BC incidence did not show a significant sex difference in any of the countries, unlike LC rates. This might suggest that the temporal pattern for smoking-attributable BC rates is less likely to be influenced by changes in individual smoking exposure levels. Alternatively, other changing population exposure levels might contribute to the temporal patterns in BC rates, for instance, SHS, a differential exposure to environmental risk factors among never-smoking women. Studies have also shown differences in the way men and women smoke their cigarettes (smoking topography). A study comparing African and European Americans showed that women tend to take smaller and shorter puffs than men. Women also tend to leave significantly longer cigarette butts, but take more puffs per cigarette than men. 33 Such detailed variations are, however, difficult to capture in this time-series analyses but could potentially dilute the estimates at the population level. Nevertheless, it remains unclear whether smoking topography has different effects on LC and BC.
The second finding regarding early slopes of BC incidence and smoking prevalence could suggest a cohort effect of a longer lag period for smoking and BC (40-50 years). Given that people generally start smoking at a young age and that the average age of onset for LC is about 10-15 years later than for BC, 19 it is likely that there is a longer lag-time between smoking and BC than between smoking and LC. 34 This also confirms that it is useful to use both LC mortality and smoking prevalence to evaluate a country's smoking habits.
Our third consistent finding illustrates the similarity in both sexes with regard to APCs for BC incidence. This might be explained by the earliest slopes of smoking prevalence data (1960s), which all showed a decline indicating the possible reduced exposure to, for instance, SHS or other environmental risk factors for BC. These findings are similar in both sexes and strengthen the findings of no sex difference for the APCs in recent BC incidences. Therefore, it is likely that other population exposure factors are explaining these sex differences for BC.
Furthermore, the recent slopes of female BC incidence in Sweden are of intermediate range, despite showing a faster annual decline in smoking prevalence in the early 1960s, with the greatest 'overall' APC for LC mortality. This could be due to differences in smokeless tobacco use which is very common in Sweden. Smokeless tobacco use is lower among females and the impact of smokeless tobacco on BC risk might be lower compared with LC risk. 35 -37 Even though this ecologic study provides some new insights into the sex differences for BC incidence trend data, some study limitations are addressed. The major limitation is the inability to draw causal inference about the effect of smoking on BC at the individual level, in conjunction with the underlying problem of heterogeneity of exposure level. 38 For example, the estimates for smoking prevalence and cigarette consumption until 1995 were estimated from several different studies, which might lead to heterogeneity of smoking information. Missing data were estimated by imputation using simple linear regression, which can be a simplified assumption and thus result in poorly estimated values. Nevertheless, the use of LC mortality rates addresses this problem, as they are a valid proxy for smoking hazards. Between-country variation due to misclassification is likely to be minimal for the outcome variables of interest, since all cancer rates were obtained from WHO databases wherein all estimates were consistently adapted to the ICD-10. Detailed annually BC incidence after 1997 was not available yet, which limited the interpretation of a lag-time effect to crude estimations. Furthermore, no detailed data were available to describe SHS exposure or potential occupational exposures, which limited this ecological study to generating hypotheses based on active smoking data alone.
Conclusions
Despite inherent methodologic limitations, this time-series analysis showed two interesting findings regarding smoking and BC rates. The results indirectly reflected a lag-time of at least 30 years between smoking and BC which is what one would expect given the age that people generally start smoking and the older age at onset for BC. On the other hand, we did not observe any sex differences in the overall direction of APCs for BC rates, suggesting the potential contribution of changes in other (smoking-related) population exposure levels regarding BC risk. Detailed data on SHS exposure or smoking topography are necessary to minimize methodologic challenges of a time-series analysis exploring such an association by sex in the future.
